Indivior Pharmaceuticals Inc cash flow to debt ratio of -7.69% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Indivior Pharmaceuticals Inc's free cash flow has decreased 1.43K% from $7.00M last year to $-93.00M, signaling decreasing performance

Indivior Pharmaceuticals Inc's debt to equity ratio is -2.45, signaling that the company spent its equity and risk bankruptcy.

Indivior Pharmaceuticals Inc's debt to equity ratio is -2.45, signaling that the company spent its equity and risk bankruptcy.

Indivior Pharmaceuticals Inc has a net debt to EBITDA ratio of 0.51x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Indivior Pharmaceuticals Inc's interest coverage ratio of 19.19 indicates that earnings with good margin can cover interest payments on company debt

Indivior Pharmaceuticals Inc's profit margin has increased (15.73K%) in the last year from 0.17% to 26.65%, signaling increasing performance

Indivior Pharmaceuticals Inc's short-term liabilities of $914.00M exceed its short-term assets of $652.00M, signaling financial risk

Indivior Pharmaceuticals Inc's return on assets of 28.79% is higher than the 5.00% threshold, indicating efficient asset utilization

Indivior Pharmaceuticals Inc's return on equity of -216.13%, is lower than 15.00%, indicating bad performance

Indivior Pharmaceuticals Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Indivior Pharmaceuticals Inc had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Indivior Pharmaceuticals Inc has negative free cash flow, indicating the company is burning cash rather than generating it

Indivior Pharmaceuticals Inc has negative free cash flow, indicating cash burn

Indivior Pharmaceuticals Inc's yearly earnings has increased 10.40K% since last year from $2.00M to $210.00M, signaling increasing performance

Indivior Pharmaceuticals Inc's yearly revenue has increased 4.29% since last year from $1.19B to $1.24B, signaling increasing performance

ROIC 125.11% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Indivior Pharmaceuticals Inc's 3-year revenue CAGR of 11.20% is positive, indicating growing revenue over the past 3 years

Indivior Pharmaceuticals Inc had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Indivior Pharmaceuticals Inc had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Indivior Pharmaceuticals Inc has insufficient data to evaluate this check.

Indivior Pharmaceuticals Inc has an earnings yield of 7.36%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Indivior Pharmaceuticals Inc is overvalued relative to its fair value price of 15.81 based on EBITDA multiple model

Indivior Pharmaceuticals Inc has an EV/EBITDA ratio of 16.30x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Indivior Pharmaceuticals Inc is overvalued relative to its fair value price of 5.69 based on Earnings Fair Value model

Indivior Pharmaceuticals Inc had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Indivior Pharmaceuticals Inc has negative shareholder equity; price-to-book is not meaningful and the check fails

Indivior Pharmaceuticals Inc has a price-to-sales ratio of 3.62x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue